About
NEC Bio B.V. develops groundbreaking therapies for patients globally using advanced AI technologies, focusing on personalized cancer vaccines and next-generation vaccines for infectious diseases. Their core approach involves identifying patient-specific neoantigens for oncology and highly immunogenic antigens for infectious diseases, leveraging proprietary AI/ML technologies like NEC Immune Profiler and NEC B-cell Epitope Predictor. They serve patients with indications including ovarian cancer, head and neck cancer, betacoronaviruses, and tropical diseases.
Tags
Performance
Company Timeline
No timeline data for this period
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does OncoImmunity do?
NEC Bio B.V. develops groundbreaking therapies for patients globally using advanced AI technologies, focusing on personalized cancer vaccines and next-generation vaccines for infectious diseases. Their core approach involves identifying patient-specific neoantigens for oncology and highly immunogenic antigens for infectious diseases, leveraging proprietary AI/ML technologies like NEC Immune Profiler and NEC B-cell Epitope Predictor. They serve patients with indications including ovarian cancer,…
How much funding has OncoImmunity raised?
OncoImmunity has raised a total of $5M in funding. The most recent round on record is Seed.
Where is OncoImmunity headquartered?
OncoImmunity is headquartered in Oslo, Norway.
When was OncoImmunity founded?
OncoImmunity was founded in 2014.
What is OncoImmunity's current status?
OncoImmunity's current operating status is: Acquired.